Drugs / Galactose
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00816504 | Dec 2008 → Dec 2009 | focal segmental glomerulosclerosis | Northwell Health | Withdrawn | No outcome recorded |
| Phase 1 | NCT00816478 | Dec 2008 → Dec 2009 | focal segmental glomerulosclerosis | Northwell Health | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04546022 | Jul → Aug 2007 | — | National Defense Medical Center, Taiwan | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00814255 | Dec 2008 → Jun 2013 | focal segmental glomerulosclerosis | NYU Langone Health | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03457311 | Sep 2013 → Mar 2018 | — | Richever Enterprise Co., Ltd. | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01882218 | Sep 2012 → May 2014 | liver cancer | University of Louisville | Withdrawn | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02702765 | Feb 2016 → Feb 2020 | Wilson disease | University of Aarhus | Completed | No outcome recorded |
| — | NCT00427986 | Jan → Mar 2007 | diabetic macular edema | Glostrup University Hospital, Copenhagen | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Galactose | “subjects will be Intravenous administered with 1.25 ml/kg G.S.P. solution (400 mg/ml of galactose) to subjects after I.V. G.SP. solution within 3 to 5 minutes” NCT04546022 ↗7“400 mg/ml of galactose” NCT03457311 ↗ |
| Known as | D-galactose | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067641 ↗ |
| Modality | Diagnostic / imaging agent | “The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine...” NCT02702765 ↗ |
| Route | Intravenous | “treatment with intravenous galactose can reduce the retinal thickness in diabetic macular oedema evaluated by OCT during a three-hour monitoring.” NCT00427986 ↗ |